Can a cancer drug help CIDP patients ditch their meds?

NCT ID NCT04480450

Terminated Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study planned to test the drug rituximab in people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. The goal was to see if rituximab could help certain patients stop their current treatments and achieve long-term remission. However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab (a drug that depletes B cells, a type of immune cell)
What this could lead to: If successful, this study could identify which CIDP patients might achieve long-term remission and stop their current medications after rituximab treatment.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. It is a small, early-phase study, and it is unclear if rituximab will work for CIDP beyond a specific subgroup.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

More trials for these conditions

Other studies related to the condition(s) this trial covers.